Multiple Sclerosis News

British Columbia Agrees To fund AUBAGIO RRMS Therapy

British Columbia’s PharmaCare drug program has announced that it will fund AUBAGIO, a therapy developed by Genzyme for the treatment of multiple sclerosis. AUBAGIO (teriflunomide) 14 mg has been officially added to PharmaCare’s provincial formulary as a first-line oral agent for patients suffering from relapsing remitting multiple sclerosis (RRMS). As…

Long-Term Multiple Sclerosis Progress Can Be Better Determined Using NEDA Standard

A study published on December 22 in JAMA Neurology emphasizes that a standard measurement used to gauge multiple sclerosis (MS) symptoms, known as “no-evidence-of-disease-activity” (NEDA) is important for determining how the disease will progress long-term. MS is the most common degenerative neurological condition that affects young adults worldwide.

Icometrix Uses Novel Brain Measurement Software in Major MS Study

Icometrix, a biotechnology company focused on unique projects for diagnosing and treating multiple sclerosis (MS) patients, has designed new software for the measurement of brain lesions and brain volumes and their changes over time. MS, a chronic and neurological condition that affects about 2.5 million people throughout the world, is often first detected in patients at…

Mapi Pharma Treats First RRMS Patient with Once-A-Month GA Depot

Mapi Pharma Ltd., a development stage pharmaceutical company specializing in the development of high-barrier to entry and high-added value generic drugs, announced it has treated the first patient in the Phase IIa study of GA Depot for relapsing-remitting multiple sclerosis (RRMS). Lead investigator Professor Ariel Miller, M.D., Ph.D., Head of the Multiple Sclerosis & Brain…

Can Tryptophan Help Improve Memory in Multiple Sclerosis Patients?

Have you ever eaten a turkey dinner and afterwards someone says that the feeling of drowsiness is caused by the tryptophan in the meat? According to Texas A&M University Professor Dr. Nicolaas Deutz, “This story about tryptophan in turkey is just kind of a running joke, it has nothing…

Can Big Data Lead to Better MS Outcomes?

In a new study, researchers based at the Imperial College, London will follow in unprecedented detail the events and experiences in lives of people with multiple sclerosis (MS) in order to improve evaluation protocols for MS treatments. MS is estimated to afflict more than two million people globally, more…

Unraveling Myelin’s Mystery With Neutron Diffraction

Researchers have uncovered new information about myelin, a fatty substance that wraps around the axons of brain cells (neurons) allowing them to transmit information quickly from one cell to another. De-myelinating diseases in which the insulating wrap is damaged include multiple sclerosis, in which unpredictable loss of myelin causes…

Failure of Brain Development in Early MS Suggests Need for Neuroprotection

Researchers from Canada and the U.S. have found that brains of young people with multiple sclerosis fail to develop fully. The article appeared November 5, 2014 in the journal Neurology entitled, “Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.” Multiple sclerosis is caused…

Review Finds MS Treatment Goals Shifted Focus in 2014

The “2014 Multiple Sclerosis Therapeutic Update,” published in the journal Neurohospitalist by author Bruce Cree, MD, PhD, MCR, provides a positive outlook on the state of current treatments and research for future treatments of multiple sclerosis. A host of new therapies, as well as common-place…

GeNeuro and Servier to Co-Develop Breakthrough Multiple Sclerosis Drug

Neurology and autoimmune therapeutics company GeNeuro SA has just announced the formation of a partnership with independent French pharmaceutical company Servier for the co-development and marketing of GNbAC1 for Multiple Sclerosis (MS). It is the first humanized monocloncal antibody treatment formulated to address one of this disease’s causal factors, making it…

Scientists Block Multiple Sclerosis in Mice Using Estrogen-Like Drug

A team of researchers at the University of California, Riverside, along with other collaborators, have identified a drug associated with estrogen, indazole chloride (Ind-Cl), that blocks the effects of multiple sclerosis (MS). The findings were reported December 1st in the Proceedings of the National Academy of Sciences. MS…

Newly Identified Immune Cell Sheds Light on Multiple Sclerosis Cause

Researchers from the National University of Singapore have found a new type of immune cell that could aid in the development of treatments for multiple sclerosis (MS). The study was published on November 21 in the journal Cell Research entitled, “STAT5 programs a distinct subset of GM-CSF-producing T helper…

Experimental Drug for RRMS, SPMS Enters Phase 2 Trial

Lexington, MA-based biopharmaceutical company Xenetic Biosciences, Inc. has just announced its new license partner Pharmsynthez has completed dosing in its ongoing Phase 2 clinical trial with pipeline product MyeloXen™ for relapsing remitting and secondary progressive (SPMS) multiple sclerosis. The MyeloXen trial is currently underway in Russia with…

New Mouse Model Better Represents JC Virus That Infects MS Patients

Researchers in the laboratory of Steve Goldman, MD, PhD, Co-Director of University of Rochester Center for Translational Neuromedicine, are delving deeper into the science behind progressive multifocal leukoencephalopathy (PML), a disease caused by the JC virus, which commonly affects multiple sclerosis patients and others with compromised immune…

Individualized Multiple Sclerosis CE Plan Wins Excellence Award

The Alliance for Continuing Education in the Health Professions, an international membership association of healthcare education professionals, has just selected the winner for the 2015 Outstanding CE Enduring Material by the Alliance for Continuing Education in the Health Professions. The winner is a joint CE activity entitled, “Confronting Current Challenges…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here